Cardio-Oncology

As cancer survival improves, cardiovascular complications of anti-cancer therapy have become a defining specialty challenge. Sessions cover anthracycline and HER2 cardiotoxicity, immune-checkpoint inhibitor myocarditis, CAR-T-related cardiac events, radiation-induced heart disease and tyrosine-kinase-inhibitor vascular toxicity. Discussion addresses risk stratification, surveillance protocols, cardio-protective medications, and the multidisciplinary cardio-oncology clinic model. The track convenes cardiologists, oncologists and clinical pharmacologists building the standardised pathways modern cancer care requires.